Showing results (41-50 of 196) with videos related to
Sort By:
Pageof 20
Biometrics|September 4, 2007
Determining the effective sample size of a parametric priorSatoshi Morita, Peter F Thall, Peter MüllerBiometrics|October 17, 2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcomeRebecca Graziani, Michele Guindani, Peter F ThallCancers|October 14, 2023
Interpreting Randomized Controlled TrialsPavlos Msaouel, Juhee Lee, Peter F ThallPharmaceutical Statistics|April 11, 2023
Generalized phase I-II designs to increase long term therapeutic success ratePeter F Thall, Yong Zang, Ying YuanJournal of the American Statistical Association|May 18, 2022
BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival ComparisonsRuitao Lin, Peter F Thall, Ying YuanPharmaceutical Statistics|January 24, 2017
A simulation study of methods for selecting subgroup-specific doses in phase 1 trialsSatoshi Morita, Peter F Thall, Kentaro TakedaPharmaceutical Statistics|July 19, 2022
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpointYun Qing, Peter F Thall, Ying YuanBiometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos MsaouelThe Annals of Applied Statistics|November 5, 2019
Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer PatientsJuhee Lee, Peter F Thall, Steven H LinBiometrics|July 14, 2005
Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun, Zheng Yuan, Peter F ThallPageof 20